Matthew J. Maurer, Ph.D.
Institution:
Johns Hopkins University, Baltimore, MDArea:
s.cerevisiae, membrane biology, ABC transporters, protein degradation mechanismsGoogle:
"Matthew Maurer"Mean distance: 21373.2 (cluster 53)
Parents
Sign in to add mentor| Susan Michaelis | grad student | 2012 | Johns Hopkins | |
| (Degradation signals for ubiquitin/proteasome-mediated cytosolic protein quality control.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Maurer MJ, Spear ED, Yu AT, et al. (2016) Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast. G3 (Bethesda, Md.) |
| Thompson CA, Maurer MJ, Allmer C, et al. (2011) Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8059 |
| Micallef IN, Maurer MJ, Nikcevich DA, et al. (2009) Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8508 |
| Metzger MB, Maurer MJ, Dancy BM, et al. (2008) Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery. The Journal of Biological Chemistry. 283: 32302-16 |
| Micallef IN, Maurer MJ, Nikcevich DA, et al. (2008) A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Journal of Clinical Oncology. 26: 8500-8500 |
| Galanis E, Jaeckle KA, Maurer MJ, et al. (2007) N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 25: 2004-2004 |
| Galanis E, Buckner JC, Maurer MJ, et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5294-304 |
| Galanis E, Buckner JC, Maurer MJ, et al. (2005) N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis Journal of Clinical Oncology. 23: 1505-1505 |
| Micallef IN, Kahl BS, Gayko U, et al. (2004) Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology. 22: 6580-6580 |